Max sheds light on the controversial amyloid hypothesis in Alzheimer's research, revealing the lack of evidence linking plaque to the disease. Drug trials targeting amyloid have a staggering 99.6% failure rate, raising questions about the direction of Alzheimer's research and treatment strategies.
